Welcome to our dedicated page for Viking Therapeutics news (Ticker: VKTX), a resource for investors and traders seeking the latest updates and insights on Viking Therapeutics stock.
Viking Therapeutics, Inc. develops clinical-stage biopharmaceutical therapies for metabolic and endocrine disorders. News about VKTX centers on VK2735, a dual GLP-1 and GIP receptor agonist being developed in subcutaneous and oral formulations for obesity and other metabolic disorders, including updates from the VANQUISH and VENTURE clinical programs.
Recurring company updates also cover financial results, corporate development, investor-conference participation, and earlier pipeline work such as an amylin agonist program. Viking's announcements typically connect clinical trial design, efficacy and safety data, regulatory interactions, and cash resources to the progress of its metabolic-disease portfolio.
Viking Therapeutics (NASDAQ: VKTX) presented 13-week Phase 2 VENTURE-Oral/Venture-2 data for once-daily oral VK2735 in adults with obesity at ECO 2026.
VK2735 produced statistically significant, dose-dependent weight loss up to 12.2% (26.6 lbs), with early, progressive reductions from Week 1 and a generally favorable tolerability profile. A related Phase 3 subcutaneous study (VANQUISH-1) design was also highlighted.
Viking Therapeutics (NASDAQ: VKTX) will present two posters on its VK2735 program at the 33rd European Congress on Obesity (ECO) in Istanbul, May 12–15, 2026. One poster reports 13-week Phase 2 VENTURE-Oral efficacy and safety data; the other describes Phase 3 VANQUISH-1 design and enrollment demographics for subcutaneous VK2735.
Both posters are on display May 12–15 at Istanbul Congress Center Level B5, with a networking session on May 14 from 18:00–19:15 Turkey Time; presenter: Karen Modesto, M.D., VP Clinical Development.
Viking (Nasdaq: VKTX) reported Q1 2026 results and clinical progress on April 29, 2026. Key items: VK2735 VANQUISH-1 fully enrolled (>4,500 patients) and VANQUISH-2 fully enrolled (~1,000 patients); oral Phase 3 for VK2735 expected 4Q26. IND filed for amylin agonist VK3019 with Phase 1 planned in 2Q26. Cash, cash equivalents and short-term investments were $603 million at March 31, 2026. R&D expense was $150.2M and net loss was $158.3M for Q1 2026.
Viking Therapeutics (NASDAQ: VKTX) will release first-quarter 2026 financial results after market close on Wednesday, April 29, 2026. A conference call to discuss results and corporate updates will begin at 4:30 p.m. ET the same day.
Live webcast access is available via Viking's Webcasts page. A telephone replay is accessible until May 6, 2026, and an archived webcast will remain on the Webcasts page for 30 days.
Viking Therapeutics (NASDAQ: VKTX) will attend multiple investor conferences in April 2026, holding management 1-on-1 meetings with investors and analysts. Events and dates: Raymond James Biotech/BioPharma Conference on April 14, 2026 in New York, and Piper Sandler Spring Biopharma Symposium on April 16, 2026 in Boston.
Viking Therapeutics (NASDAQ: VKTX) announced completion of enrollment in the Phase 3 VANQUISH-2 trial of subcutaneous VK2735, a GLP-1/GIP dual agonist. The randomized, double-blind, placebo-controlled study enrolled ~1,000 adults with type 2 diabetes and obesity/overweight, with 78-week dosing and a primary endpoint of percent body weight change at week 78.
The trial randomized participants to VK2735 7.5 mg, 12.5 mg, 17.5 mg or placebo, includes a 52-week extension, and follows VANQUISH-1 (enrollment completed Nov 2025). Phase 1 maintenance dosing results are expected in Q3 2026.
Viking Therapeutics (NASDAQ: VKTX) announced participation at two investor conferences in Miami the week of March 8–11, 2026. Management will hold a fireside chat on March 10, 2026 at 10:40–11:10 a.m. ET at the Leerink Partners Global Healthcare Conference and conduct 1-on-1 investor meetings at Leerink and the Jefferies Biotech on the Beach Summit (March 10–11).
A live webcast of the Leerink fireside chat will be available via the company's Investors & Media — Webcasts page, with a replay posted on the website after the conference.
Viking Therapeutics (Nasdaq: VKTX) reported Q4 and full-year 2025 results and provided a corporate update highlighting rapid clinical progress in obesity programs.
Key points: strong cash position of $706 million, VANQUISH-1 enrollment >4,500, oral VK2735 to enter Phase 3 in 3Q26, maintenance dosing study fully enrolled with data expected 3Q26, and an IND for a dual amylin/calcitonin agonist planned in 1Q26.
Viking Therapeutics (NASDAQ: VKTX) will release fourth-quarter and year-end 2025 financial results after market close on Wednesday, February 11, 2026. A conference call to discuss results and corporate updates begins at 4:30 p.m. ET the same day.
Investors can join by phone or listen via webcast at the company's Webcasts page; a telephone replay is available through February 18, 2026 and the webcast archive will remain on the site for 30 days.
Viking Therapeutics (NASDAQ: VKTX) announced publication in Obesity of Phase 2 VENTURE results for weekly subcutaneous VK2735, a dual GLP-1/GIP receptor agonist. The 13-week trial met its primary and secondary endpoints, showing mean body-weight reductions up to 14.7% from baseline with no plateau and a safety profile in which most adverse events were reported as mild or moderate. Viking is advancing VK2735 in the registrational VANQUISH Phase 3 program (78-week dosing); VANQUISH-1 has ~4,650 participants enrolled and VANQUISH-2 is enrolling ~1,100. An exploratory maintenance study (≈180 subjects) also completed enrollment.